Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.84
(-1.56%)
SEK 8.84
(-1.56%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 755.1 Million SEK | -0.64% |
| 2022 | 759.96 Million SEK | 32.85% |
| 2021 | 572.03 Million SEK | 19.24% |
| 2020 | 479.71 Million SEK | -18.26% |
| 2019 | 586.86 Million SEK | 17.17% |
| 2018 | 500.84 Million SEK | 20.25% |
| 2017 | 416.49 Million SEK | 14.32% |
| 2016 | 364.33 Million SEK | 15.48% |
| 2015 | 315.48 Million SEK | 12.69% |
| 2014 | 279.94 Million SEK | 26.84% |
| 2013 | 220.71 Million SEK | -19.81% |
| 2012 | 275.23 Million SEK | 1.24% |
| 2011 | 271.84 Million SEK | 31.89% |
| 2010 | 206.11 Million SEK | 37.99% |
| 2009 | 149.36 Million SEK | -11.28% |
| 2008 | 168.36 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 797.3 Million SEK | 5.59% |
| 2024 Q3 | 538.5 Million SEK | -32.93% |
| 2024 Q2 | 802.9 Million SEK | 0.7% |
| 2023 Q2 | 778.7 Million SEK | 1.92% |
| 2023 FY | 755.1 Million SEK | -0.64% |
| 2023 Q4 | 755.1 Million SEK | -3.77% |
| 2023 Q3 | 784.7 Million SEK | 0.77% |
| 2023 Q1 | 764 Million SEK | 0.53% |
| 2022 Q3 | 692.2 Million SEK | 7.57% |
| 2022 Q1 | 609.3 Million SEK | 6.52% |
| 2022 Q4 | 759.96 Million SEK | 9.79% |
| 2022 FY | 759.96 Million SEK | 32.85% |
| 2022 Q2 | 643.5 Million SEK | 5.61% |
| 2021 Q4 | 572.03 Million SEK | 5.7% |
| 2021 FY | 572.03 Million SEK | 19.24% |
| 2021 Q1 | 514.4 Million SEK | 7.23% |
| 2021 Q3 | 541.2 Million SEK | 3.01% |
| 2021 Q2 | 525.4 Million SEK | 2.14% |
| 2020 Q3 | 557.1 Million SEK | -1.42% |
| 2020 FY | 479.71 Million SEK | -18.26% |
| 2020 Q1 | 627.7 Million SEK | 6.96% |
| 2020 Q2 | 565.1 Million SEK | -9.97% |
| 2020 Q4 | 479.71 Million SEK | -13.89% |
| 2019 Q3 | 597.2 Million SEK | 7.66% |
| 2019 FY | 586.86 Million SEK | 17.17% |
| 2019 Q1 | 554 Million SEK | 10.61% |
| 2019 Q2 | 554.7 Million SEK | 0.13% |
| 2019 Q4 | 586.86 Million SEK | -1.73% |
| 2018 Q2 | 436.9 Million SEK | 3.7% |
| 2018 Q4 | 500.84 Million SEK | 15.03% |
| 2018 FY | 500.84 Million SEK | 20.25% |
| 2018 Q1 | 421.3 Million SEK | 1.15% |
| 2018 Q3 | 435.4 Million SEK | -0.34% |
| 2017 Q1 | 378.2 Million SEK | 3.81% |
| 2017 Q4 | 416.49 Million SEK | 5.41% |
| 2017 Q3 | 395.1 Million SEK | 4.94% |
| 2017 Q2 | 376.5 Million SEK | -0.45% |
| 2017 FY | 416.49 Million SEK | 14.32% |
| 2016 Q2 | 308.5 Million SEK | 9.09% |
| 2016 FY | 364.33 Million SEK | 15.48% |
| 2016 Q4 | 364.33 Million SEK | 6.65% |
| 2016 Q3 | 341.6 Million SEK | 10.73% |
| 2016 Q1 | 282.8 Million SEK | -10.36% |
| 2015 Q2 | 286.8 Million SEK | -0.9% |
| 2015 Q4 | 315.48 Million SEK | 8.3% |
| 2015 Q3 | 291.3 Million SEK | 1.57% |
| 2015 Q1 | 289.4 Million SEK | 3.38% |
| 2015 FY | 315.48 Million SEK | 12.69% |
| 2014 FY | 279.94 Million SEK | 26.84% |
| 2014 Q2 | 238.3 Million SEK | 9.77% |
| 2014 Q4 | 279.94 Million SEK | 8.68% |
| 2014 Q3 | 257.6 Million SEK | 8.1% |
| 2014 Q1 | 217.1 Million SEK | -1.64% |
| 2013 Q2 | 312.22 Million SEK | 10.23% |
| 2013 Q1 | 283.24 Million SEK | 2.91% |
| 2013 FY | 220.71 Million SEK | -19.81% |
| 2013 Q4 | 220.71 Million SEK | -1.47% |
| 2013 Q3 | 224.01 Million SEK | -28.25% |
| 2012 Q2 | 254.14 Million SEK | 5.46% |
| 2012 Q3 | 251.8 Million SEK | -0.92% |
| 2012 Q4 | 275.23 Million SEK | 9.3% |
| 2012 FY | 275.23 Million SEK | 1.24% |
| 2012 Q1 | 240.99 Million SEK | -11.35% |
| 2011 Q1 | 206.08 Million SEK | -0.01% |
| 2011 Q4 | 271.84 Million SEK | 3.18% |
| 2011 Q3 | 263.48 Million SEK | -4.47% |
| 2011 Q2 | 275.81 Million SEK | 33.83% |
| 2011 FY | 271.84 Million SEK | 31.89% |
| 2010 Q4 | 206.11 Million SEK | 0.0% |
| 2010 FY | 206.11 Million SEK | 37.99% |
| 2009 FY | 149.36 Million SEK | -11.28% |
| 2008 FY | 168.36 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -1100.782% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 77.03% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 77.03% |
| Arcoma AB | 81.96 Million SEK | -821.281% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | -10.576% |
| BICO Group AB (publ) | 10.19 Billion SEK | 92.595% |
| CellaVision AB (publ) | 928.71 Million SEK | 18.694% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -1208.099% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -3339.233% |
| C-Rad AB (publ) | 404 Million SEK | -86.906% |
| Duearity AB (publ) | 15.14 Million SEK | -4886.133% |
| Dignitana AB (publ) | 44.83 Million SEK | -1584.326% |
| Episurf Medical AB (publ) | 104.3 Million SEK | -623.969% |
| Getinge AB (publ) | 55.09 Billion SEK | 98.63% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | -635.69% |
| Iconovo AB (publ) | 128.07 Million SEK | -489.554% |
| Integrum AB (publ) | 164.85 Million SEK | -358.027% |
| Luxbright AB (publ) | 40.68 Million SEK | -1755.891% |
| Mentice AB (publ) | 322.52 Million SEK | -134.121% |
| OssDsign AB (publ) | 356.38 Million SEK | -111.875% |
| Paxman AB (publ) | 167.12 Million SEK | -351.818% |
| Promimic AB (publ) | 92.87 Million SEK | -713.028% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -1833.873% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -1073.718% |
| ScandiDos AB (publ) | 81.47 Million SEK | -826.81% |
| Sectra AB (publ) | 3.21 Billion SEK | 76.484% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 25.537% |
| Senzime AB (publ) | 433.54 Million SEK | -74.17% |
| SpectraCure AB (publ) | 144.83 Million SEK | -421.355% |
| Stille AB | 804.89 Million SEK | 6.186% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 95.393% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 65.609% |